Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon)

Circulation

Volumn 135, Issue 23, 2017, Pages 2227-2236

  Schroeder, Henrik ^a   Werner, Martin ^b   Meyer, Dirk Roelfs ^c   Reimer, Peter ^d   Krüger, Karsten ^e,f   Jaff, Michael R ^g   Brodmann, Marianne ^h  

^a Jewish Hospital Berlin   (Germany)

^b HANUSCH HOSPITAL   (Austria)

^c St Hubertus Hospital   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e VIVANTES HOSPITAL   (Germany)

^f Vivantes Klinikum Spandau   (Germany)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Drug eluting balloon; Paclitaxel; Percutaneous treatment; Peripheral artery disease; Randomized controlled trial

Indexed keywords

PACLITAXEL; BIOCOMPATIBLE COATED MATERIAL;

AGED; AMPUTATION; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FEMORAL ARTERY; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LOW DRUG DOSE; MALE; MULTICENTER STUDY; PATIENT SAFETY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUPERFICIAL FEMORAL ARTERY; TARGET LESION REVASCULARIZATION; VASCULAR PATENCY; ANGIOPLASTY; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; EUROPE; MIDDLE AGED; PATHOLOGY; PERIPHERAL ARTERIAL DISEASE; PROCEDURES; SINGLE BLIND PROCEDURE; TIME FACTOR; TREATMENT OUTCOME; TRENDS;

AGED; ANGIOPLASTY; ANGIOPLASTY, BALLOON; COATED MATERIALS, BIOCOMPATIBLE; EUROPE; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 85018663703     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.026493     Document Type: Article

References (20)

1. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, Creager MA, Easton JD, Gavin JR 3rd, Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Smith SC, Sullivan F, Weber MA; Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: A call to action. Arch Intern Med. 2003;163:884-892. doi: 10.1001/archinte.163.8.884.
2. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, Mc-Dermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet. 2013;382:1329-1340. doi: 10.1016/S0140-6736(13)61249-0.
3. Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, Müller-Hülsbeck S, Nehler MR, Benenati JF, Scheinert D; LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145-153. doi: 10.1056/NEJMoa1406235.
4. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, Metzger C, Scheinert D, Zeller T, Cohen DJ, Snead DB, Alexander B, Landini M, Jaff MR; IN.PACT SFA Trial Investigators. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495-502. doi: 10.1161/CIRCULATIONAHA.114.011004.
5. Vardi M, Novack V, Pencina MJ, Doros G, Burke DA, Elmariah S, Cutlip DE, Mauri L, Yeh RW. Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: A meta-analysis and critical examination of current methodologies. Catheter Cardiovasc Interv. 2014;83:975-983. doi: 10.1002/ccd.25179.
6. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Zeller T, Roubin GS, Burket MW, Khatib Y, Snyder SA, Ragheb AO, White JK, Machan LS; Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: Twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495-504. doi: 10.1161/CIRCINTERVENTIONS.111.962324.
7. Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M, Ruhlmann C, Kavteladze Z, Lottes AE, Ragheb AO, Zeller T; Zilver PTX Single-Arm Study Investigators. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: Twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther. 2011;18:613-623. doi: 10.1583/11-3560.1.
8. Schroeder H, Meyer DR, Lux B, Ruecker F, Martorana M, Duda S. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: Outcomes from the ILLUMENATE first-in-human study. Catheter Cardiovasc Interv. 2015;86:278-286. doi: 10.1002/ccd.25900.
9. Kinstner CM, Lammer J, Willfort-Ehringer A, Matzek W, Gschwandtner M, Javor D, Funovics M, Schoder M, Koppensteiner R, Loewe C, Ristl R, Wolf F. Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-Year Results of the PACUBA Trial. JACC Cardiovasc Interv. 2016;9:1386-1392. doi: 10.1016/j.jcin.2016.04.012.
10. Laird JR, Schneider PA, Tepe G, Brodmann M, Zeller T, Metzger C, Krishnan P, Scheinert D, Micari A, Cohen DJ, Wang H, Hasenbank MS, Jaff MR; IN.PACT SFA Trial Investigators. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66:2329-2338. doi: 10.1016/j.jacc.2015.09.063.
11. Giacoppo D, Cassese S, Harada Y, Colleran R, Michel J, Fusaro M, Kastrati A, Byrne RA. Drug-coated balloon versus plain balloon angioplasty for the treatment of femoropopliteal artery disease: An updated systematic review and meta-analysis of randomized clinical trials. JACC Cardiovasc Interv. 2016;9:1731-1742. doi: 10.1016/j.jcin.2016.06.008.
12. Gongora CA, Shibuya M, Wessler JD, McGregor J, Tellez A, Cheng Y, Conditt GB, Kaluza GL, Granada JF. Impact of paclitaxel dose on tissue pharmacokinetics and vascular healing: A comparative drug-coated balloon study in the familial hypercholesterolemic swine model of superficial femoral in-stent restenosis. JACC Cardiovasc Interv. 2015;8:1115-1123. doi: 10.1016/j.jcin.2015.03.020.
13. Milewski K, Afari ME, Tellez A, Aboodi MS, Kim JS, Cheng Y, Conditt GB, McGregor JC, Yi GH, Stenoien M, Langanki D, Krueger CG, Kaluza GL, Granada JF. Evaluation of efficacy and dose response of different paclitaxel-coated balloon formulations in a novel swine model of iliofemoral in-stent restenosis. JACC Cardiovasc Interv. 2012;5:1081-1088. doi: 10.1016/j.jcin.2012.06.012.
14. Cremers B, Biedermann M, Mahnkopf D, Böhm M, Scheller B. Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol. 2009;98:325-330. doi: 10.1007/s00392-009-0008-2.
15. Katsanos K. Paclitaxel-coated balloons in the femoropopliteal artery: It is all about the pharmacokinetic profile and vessel tissue bioavailability. JACC Cardiovasc Interv. 2016;9:1743-1745. doi: 10.1016/j.jcin.2016.06.047.
16. Kolodgie FD, Pacheco E, Yahagi K, Mori H, Ladich E, Virmani R. Comparison of particulate embolization after femoral artery treatment with IN.PACT Admiral versus Lutonix 035 paclitaxel-coated balloons in healthy swine. J Vasc Interv Radiol. 2016;27:1676-1685.e2. doi: 10.1016/j.jvir.2016.06.036.
17. Laurich C. Lutonix Global Real World SFA Registry: Interim results & first look at LEVANT 2 24 month results. http://investorrelations. crbard.com/phoenix.zhtmlc=91501&p=irol-sec&secCat01.1-rs=71&secCat01.1-rc=10&control-searchbox=&control-year=2015&control-selectgroup=0. Accessed February 25, 2017.
18. Abularrage CJ, Conrad MF, Hackney LA, Paruchuri V, Crawford RS, Kwolek CJ, LaMuraglia GM, Cambria RP. Long-term outcomes of diabetic patients undergoing endovascular infrainguinal interventions. J Vasc Surg. 2010;52:314-22.e1. doi: 10.1016/j.jvs. 2010.03.015.
19. US Food and Drug Administration. Summary of safety and effectiveness data (SSED): LUTONIX® 035 Drug Coated Balloon PTA Catheter. http://www.accessdata.fda.gov/cdrh-docs/pdf13/P130024S009B.pdf. Accessed February 25, 2017.
20. Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G; VIVA Physicians, Inc. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007;69:910-919. doi: 10.1002/ccd.21104.